In this task, you're given a paragraph and title from the research paper. Your task is to classify whether the given title is suitable or not for the research paper based on the given paragraph. Return "True" if title is proper according to paragraph else "False".

Q: Paragraph: The Republic of Korea has not only monumentally progressed socially, economically, and politically since 1948, but has taken the arduous undertaking of reforming the way it reduces disaster risk, mitigates the impact, and prepares for and responds to disasters for a resilient future. The administrative and organizational reforms have not been without its setbacks or obstacles; however, they were not so insurmountable that they could not be overcome by one of Korea's greatest assets: persisting endeavors to build back better and to enhance resilience. Starting with an independent national agency in 2004 to manage natural and human-caused disasters and preparedness, the government quickly realized, through focusing events, it was insufficient to handle the increasing complexity and intensifying of disasters striking the nation. Therefore, through political will and hindsight, it continuously coalesced pertinent disaster management responsibilities into newer and newer agencies until 2016, when it enacted a progressively more ubiquitous and self-propelling agency. However, although the agency is apt for current disasters, it will not be for future disaster, which needs the integration of resilience into Disaster Risk Management (DRM). Therefore, we suggest five tenets on how to make Korea's resilient future as well as for other nations that are and will follow in Korea's footsteps, especially for those nations in Asia and Africa. A future that is resilient against all types of disaster risks, especially being prepared well for "low probability and high impact" focusing events that are located in the long-tail of the Power-law Distribution.
Title: Disaster Resilient Future in Korea Resilience Sustainable Development Goals (SDGs) Climate Change Ministry of Public Safety and Security (MPSS) Sendai Framework for Disaster Risk Reduction Conference of Parties (COP)

A: True
****
Q: Paragraph: The SARS 3C-like proteinase (SARS-3CLpro), which is the main proteinase of the SARS coronavirus, is essential to the virus life cycle. This enzyme has been shown to be active as a dimer in which only one protomer is active. However, it remains unknown how the dimer structure maintains an active monomer conformation. It has been observed that the Ser139-Leu141 loop forms a short 3 10 -helix that disrupts the catalytic machinery in the inactive monomer structure. We have tried to disrupt this helical conformation by mutating L141 to T in the stable inactive monomer G11A/R298A/Q299A. The resulting tetra-mutant G11A/L141T/R298A/Q299A is indeed enzymatically active as a monomer. Molecular dynamics simulations revealed that the L141T mutation disrupts the 3 10 -helix and helps to stabilize the active conformation. The coil-3 10 -helix conformational transition of the Ser139-Leu141 loop serves as an enzyme activity switch. Our study therefore indicates that the dimer structure can stabilize the active conformation but is not a required structure in the evolution of the active enzyme, which can also arise through simple mutations.
Title: Conformational Flexibility of a Short Loop near the Active Site of the SARS-3CLpro is Essential to Maintain Catalytic Activity OPEN

A: True
****
Q: Paragraph: Neonates are at high risk for influenza morbidity and mortality due to immune immaturity and lack of priming by prior influenza virus exposure. Inactivated influenza vaccines are ineffective in infants under six months and to provide protection in older children generally require two doses given a month apart. This leaves few options for rapid protection of infants, e.g. during an influenza pandemic. We investigated whether Advax TM , a novel polysaccharide adjuvant based on delta inulin microparticles could help overcome neonatal immune hypo-responsiveness. We first tested whether it was possible to use Advax to obtain single-dose vaccine protection of neonatal pups against lethal influenza infection. Inactivated influenza A/H1N1 vaccine (iH1N1) combined with Advax TM adjuvant administered as a single subcutaneous immunization to 7-day-old mouse pups significantly enhanced serum influenzaspecific IgM, IgG1, IgG2a and IgG2b levels and was associated with a 3-4 fold increase in the frequency of splenic influenza-specific IgM and IgG antibody secreting cells. Pups immunized with Advax had significantly higher splenocyte influenza-stimulated IFN-, IL-2, IL-4, and IL-10 production by CBA and a 3-10 fold higher frequency of IFN-, IL-2, IL-4 or IL-17 secreting T cells by ELISPOT. Immunization with iH1N1 + Advax induced robust protection of pups against virus challenge 3 weeks later, whereas pups immunized with iH1N1 antigen alone had no protection. Protection by Advax-adjuvanted iH1N1 was dependent on memory B cells rather than memory T cells, with no protection in neonatal MT mice that are B-cell deficient. Hence, Advax adjuvant overcame neonatal immune hypo-responsiveness and enabled single-dose protection of pups against otherwise lethal influenza infection, thereby supporting ongoing development of Advax TM as a neonatal vaccine adjuvant.
Title: Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single-dose influenza vaccine protection

A:
True
****